Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Placenta. 2010 Jan 27;31(Suppl):S66–S69. doi: 10.1016/j.placenta.2009.12.021

Reactive Oxygen and Nitrogen Species and Functional Adaptation of the Placenta

Leslie Myatt 1
PMCID: PMC2832707  NIHMSID: NIHMS167490  PMID: 20110125

Abstract

The placenta regulates fetal growth and development via transport of nutrients and gases, and synthesis and secretion of steroid and peptide hormones. These functions are determined by vascular development and blood flow and by growth and differentiation of the trophoblast, which contains receptors, transporters and enzymes. The placenta generates reactive oxygen species which may contribute to the oxidative stress seen even in normal pregnancy but this is increased in pregnancies complicated by preeclampsia, IUGR and pregestational diabetes where oxidative and nitrative stress have been clearly documented. Nitrative stress is the covalent modification of proteins and DNA by peroxynitrite formed by the interaction of superoxide and nitric oxide. We have demonstrated nitrative stress by localizing nitrotyrosine residues in these placentas and found increased expression of NADPH oxidase (NOX) enzyme isoforms 1 and 5 as a potential source of superoxide generation. The presence of nitrative stress was associated with diminished vascular reactivity of the fetal placental circulation, a situation that could be reproduced by treatment with peroxynitrite in vitro. We find many nitrated proteins in the placenta, including p38 MAP kinase which has a role in development of the villous vasculature. Nitration of p38 MAPK was increased in the preeclamptic placenta and associated with loss of catalytic activity. We hypothesize that nitration of proteins in the placenta including receptors, transporters, enzymes and structural proteins can alter protein and placental function and this influences fetal growth and development. Increasing nitrative stress but a decrease in oxidative stress, measured as protein carbonylation, is found in the placenta with increasing BMI. Formation of peroxynitrite may then consume superoxide, decreasing nitrative stress. As protein carbonylation is a covalent modification at Lys, Arg, Pro and Thr residues the switch from carbonylation to nitration at tyrosine residues may alter protein function and hence placental function.

1. Introduction

The placenta has crucial role in pregnancy as the interface between mother and fetus. It anchors the conceptus, provides an interface for the exchange and modification of nutrients and gases, synthesizes and secretes a range of steroid and peptide hormones as well as providing an immune barrier between the mother and the semi-allogeneic fetus. There is a large volume of literature that link abnormalities in each of these aspects of placental function with poor perinatal outcome. These include defective trophoblast invasion, which may have immune causes, and abnormalities in hormone production, placental blood flows and nutrient transfer that are associated with poor fetal growth. Historically there has been a focus on the role of abnormal trophoblast invasion, maldevelopment of uterine blood flow and thus supply of nutrients, and generation of an ischemia/reperfusion type injury in regulation of fetal growth. More recently, however, there has been a renewed focus on the roles that expression and activity of nutrient transporters on the trophoblast surface play in fetal growth and development. The determinants of fetal growth are now recognized to be (a) those that are vascular (flow) dependent and regulated by remodeling, vasculogenesis and angiogenesis in uterine and fetal placental vasculatures [12] and (b) those that are trophoblast or membrane dependent and regulated by exchange surface area and thickness, transporter expression [3] and activity and hormone production [4] and metabolism. These in turn depend on trophoblast proliferation and differentiation.

2. The effect of timing of a placental “insult”

The placenta is in a constant state of growth and differentiation throughout gestation with development of the vasculature and the trophoblast occurring at different times in a highly regulated manner. An “insult” applied to this developmental process at any time may have an effect on subsequent placental function and hence fetal growth and development [5]. When the normal pattern of fetal growth and development is disrupted by an abnormal stimulus or “insult” applied at a critical point in in utero development “fetal programming” occurs. Fetal programming may determine the risk of disease in later life [6]. Equally the same insult applied to the placenta at different times may give divergent effects. For example in pregnancies complicated by insulin dependent diabetes mellitus with a LGA baby, increased Glut1 expression is seen in the basement membrane of trophoblast together with increased system A amino acid transporter [7]. However gestational diabetes plus an LGA baby shows no change in basement membrane Glut 1 but an increase in system A transporter [8]. This observation is consistent with hyperglycemia causing increased Glut 1 in the first trimester.

3. Generation of oxidative and nitrative stress in the placenta

The defective trophoblast invasion seen with preeclampsia or IUGR is thought to lead to a relative hypoxia [9] in the villous placenta or an ischemia/reperfusion type injury [10]. This then leads to a heightened inflammatory response in turn giving oxidative [11] and nitrative stress [12]. We hypothesize that oxidative and nitrative stress can lead to altered placental function via covalent modification of protein structure and function. Measurements of markers of oxidative stress in maternal blood and urine [1315] show that pregnancy per se is a state of oxidative stress due to the high metabolic activity of the placenta and maternal metabolism in pregnancy. However, this is heightened in pregnancies complicated by preeclampsia, IUGR and diabetes as measured by increased markers of production of reactive oxygen species and decreases in antioxidant defences [11, 1618].

The placenta produces many reactive oxygen species but the focus of this discussion will be superoxide, nitric oxide and peroxynitrite. These reactive oxygen species have differing half lives which in turn determine their potential diffusion distances in the placenta. The diffusion distance of superoxide is 0.4 μm in one half life, this limiting it to an intracrine action within the cell of synthesis. In contrast the diffusion distance of NO is 100 μm allowing it to cross the distance of an intermediate stem villous and act as a paracrine mediator in adjacent cells. Indeed NO produced by endothelial cells can act on underlying smooth muscle. The diffusion distance of peroxynitrite is 5 μm (the thickness of the trophoblast membrane) [19], meaning again it acts locally. Indeed we find evidence of peroxynitrite action very locally in the vascular endothelium and surrounding stroma of pregnancies complicated by pregestational diabetes or preeclampsia [12, 20]. Placental production of superoxide is increased in preeclampsia. There may be several cellular sources in the placenta including the mitochondrial electron transport chain [21], xanthine oxidase [22] and NADPH oxidase (NOX) [23], Previously Raijmakers et al [24] had provided evidence for an increase in NOX-dependent superoxide generation in the placenta in preeclampsia. There is now recognized to be a superfamily of NOX enzymes [25]. In addition to their well recognized role in host defence the NOX enzymes may function in oxygen sensing, control of cell proliferation and intercellular signaling but may also have roles in pathologies such as atherosclerosis and vascular smooth muscle hypertrophy [26]. We have cloned NOX 1 and 5 isoforms from human trophoblast [27] and found that expression of both isoforms was increased in syncytiotrophoblast, vascular endothelium and stromal cells of the placenta in preeclampsia and may account for the increased superoxide generation.

4. Peroxynitrite and nitrotyrosine

When endothelium derived relaxing factor was identified as nitric oxide it was pharmacologically defined by the ability of superoxide to scavenge EDRF or NO and the ability of superoxide dismutase (which scavenges superoxide) to prolong the half life of NO [28]. Under conditions of increased superoxide and NO production they react together to produce a more long-lived and potent pro-oxidant, peroxynitrite [19]. Peroxynitrite characteristically nitrates tyrosine residues in proteins to produce nitrotyrosine [29]. Nitrotyrosine is measured, either by ELISA or immunohistochemistry, as an index of peroxynitrite production and action. This nitration and covalent modification of proteins and DNA is described as nitrative stress. Nitrotyrosine residues were first described in atherosclerotic plaques [30] but have now been described in many inflammatory situations including by ourselves in the placenta of pregnancies complicated by preeclampsia [12] or pre-gestational diabetes [20]. What then are the consequences of protein nitration? The description of the occurrence of nitrotyrosine in many pathologic situations led to the belief that nitration was a terminal event, where proteins lost activity and there was cellular damage. Indeed nitration targets proteins to the proteosome [31]. However nitration is increasingly thought of as a selective, reversible physiologic process with beneficial as well as detrimental effects. Indeed covalent modification by nitration gives loss of function in many proteins eg SOD [32] and PGI2 synthase [33], but a gain of function in others eg PARP [34] and COX-2 [35]. Within any cell many proteins are found to be nitrated and include cytosolic, membrane, mitochondrial and structural proteins [36]. The covalent modification by nitration is akin to a phosphorylation. Indeed the addition of a negatively charged nitrate group can in some cases mimic phosphorylation. However to date no equivalent of the phosphatase i.e. the denitrase activity has been isolated although there is evidence that cellular homogenates possess a denitrase-like activity [37]. There is also evidence from in vitro studies of a denitrase-like activity in other cell systems [3839]. Recent work with mitochondrial protein nitration has revealed a nitration consensus sequence [40]. Protein nitration may also be residue, protein and tissue specific with not all tyrosine residues of a protein being nitrated and not all proteins nitrated [41]) depending on cellular location of protein, and the peroxynitrite generating system [42], the concentration of peroxynitrite and interaction with other molecules.

5. Functional consequences of protein nitration

What then is the functional consequence of protein nitration in the placenta? We first described the presence of nitrotyrosine residues in the vascular endothelium and surrounding stroma and in syncytiotrophoblast of placentas from pregnancies complicated by preeclampsia and pregestational diabetes [12, 20]. This was associated with an attenuated vascular reactivity in these placentas [43]. We could recapitulate these findings in the placental vasculature treated in vitro with peroxynitrite which led to attenuated vascular reactivity and the presence of nitrotyrosine residues [43] suggesting that peroxynitrite did indeed cause alterations in vascular reactivity by nitration of proteins in the fetal placental vasculature. The search for nitrated proteins in the placenta can be performed in two ways, either by screening for all nitrated proteins or by examination of selected proteins using immunoblotting, immunprecipitation and mass spectrometry techniques. P38MAP kinase is critical for placental development as p38 MAP kinase null mice show embryonic lethality with decreased labyrinthine and spongiotrophoblast layers and decreased vascularization of the labyrinth [44]. We subsequently identified p38 MAP kinase as a nitrated protein in the placenta [45], that in vitro p38 MAP kinase could be nitrated with peroxynitrite at tyrosine residues, and further that this was associated with a loss of catalytic activity [46]. This data strongly suggests that nitrative stress and covalent modification of protein function may have an effect on placental function.

Subsequently we have identified many nitrated proteins in the placenta. Nitrated proteins are found in the normal placenta and in increased amounts in placentas from pregnancies complicated by preeclampsia and pregestational diabetes. These include acetyl CoA acyltransferase, p53, P2X4 purinergic receptors [47] and the taurine transporter among others. Potentially any protein in the placenta is a target for nitration including enzymes, receptors, transporters, signal transduction molecules, structural proteins and steroid hormones. The covalent modification of any of these molecules potentially can alter protein and then placental function and thus fetal growth and development (Figure 1).

Figure 1.

Figure 1

Targets and Effects of Protein Nitration In the Placenta

6. Obesity and oxidative and nitrative stress

Obesity is a growing problem in the US and many other developed countries. Fifty seven percent of women of reproductive age in the US are overweight (BMI>25) and 30% are obese (BMI>30). Obesity during pregnancy is associated with maternal complications and poor perinatal outcome, including development of pregnancy induced hypertension, diabetes, an increased rate of cesarean section and its complications, prematurity, stillbirth and macrosomia [4849]. As adults the offspring of such pregnancies show an increased incidence of obesity, insulin resistance, hypertension and cardiovascular disease [50]. Obesity also leads to increased production of inflammatory cytokines [5152] which in turn can lead to increased oxidative and nitrative stress. We hypothesized that with increasing BMI there would be increased oxidative and nitrative stress in the placenta. We collected placental tissue from lean (BMI 18.5–24.9), overweight (BMI 25–25.9) and obese (BMI 30–40) and measured oxidative stress via measurement of protein carbonyls and nitrative stress by measurement of nitrotyrosine residues. Interestingly we found that with increasing BMI there was increasing concentrations of nitrotyrosine residues but conversely decreasing concentrations of protein carbonyls [53]. We hypothesize that increasing nitrative stress draws superoxide radicals away from oxidative effects towards formation of peroxynitrite. Protein carbonylation is another covalent modification but with carbonyls being placed on lysine arginine, proline and threonine residues, Modification of proteins at these residues may give distinct functional effects from that of nitration at tyrosine residues. Thus the balance between oxidative and nitrative stress or carbonylation vs nitration may alter placental function. Our data therefore suggest that in addition to under- or overnutrition, changes in diet or exposure to inappropriate developmental signals or stress that ischemia/reperfusion injury and oxidative/nitrative stress may affect placental function and hence fetal growth and development.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Krebs C, Macara LM, Leiser R, Bowman AW, Greer IA, Kingdom JC. Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree. Am J Obstet Gynecol. 1996;175(6):1534–42. doi: 10.1016/s0002-9378(96)70103-5. [DOI] [PubMed] [Google Scholar]
  • 2.Vonnahme KA, Ford SP. Differential expression of the vascular endothelial growth factor-receptor system in the gravid uterus of yorkshire and Meishan pigs. Biol Reprod. 2004;71(1):163–9. doi: 10.1095/biolreprod.103.026344. [DOI] [PubMed] [Google Scholar]
  • 3.Johansson M, Glazier JD, Sibley CP, Jansson T, Powell TL. Activity and protein expression of the Na+/H+ exchanger is reduced in syncytiotrophoblast microvillous plasma membranes isolated from preterm intrauterine growth restriction pregnancies. J Clin Endocrinol Metab. 2002;87(12):5686–94. doi: 10.1210/jc.2002-020214. [DOI] [PubMed] [Google Scholar]
  • 4.McMullen S, Osgerby JC, Thurston LM, Gadd TS, Wood PJ, Wathes DC, Michael AE. Alterations in placental 11 beta-hydroxysteroid dehydrogenase (11 betaHSD) activities and fetal cortisol:cortisone ratios induced by nutritional restriction prior to conception and at defined stages of gestation in ewes. Reproduction. 2004;127(6):717–25. doi: 10.1530/rep.1.00070. [DOI] [PubMed] [Google Scholar]
  • 5.Myatt L. Placental Adaptive Responses and Fetal Programming. J Physiol. 2006 doi: 10.1113/jphysiol.2006.104968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Barker DJ. The origins of the developmental origins theory. J Intern Med. 2007;261(5):412–7. doi: 10.1111/j.1365-2796.2007.01809.x. [DOI] [PubMed] [Google Scholar]
  • 7.Jansson T, Wennergren M, Powell TL. Placental glucose transport and GLUT 1 expression in insulin-dependent diabetes. Am J Obstet Gynecol. 1999;180(1 Pt 1):163–8. doi: 10.1016/s0002-9378(99)70169-9. [DOI] [PubMed] [Google Scholar]
  • 8.Jansson T, Ekstrand Y, Wennergren M, Powell TL. Placental glucose transport in gestational diabetes mellitus. Am J Obstet Gynecol. 2001;184(2):111–6. doi: 10.1067/mob.2001.108075. [DOI] [PubMed] [Google Scholar]
  • 9.Burton GJ, Caniggia I. Hypoxia: implications for implantation to delivery-a workshop report. Placenta. 2001;22 (Suppl A):S63–5. doi: 10.1053/plac.2001.0642. [DOI] [PubMed] [Google Scholar]
  • 10.Hung TH, Skepper JN, Burton GJ. In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol. 2001;159(3):1031–43. doi: 10.1016/S0002-9440(10)61778-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wang Y, Walsh SW. Increased superoxide generation is associated with decreased superoxide dismutase activity and mRNA expression in placental trophoblast cells in pre-eclampsia. Placenta. 2001;22(2–3):206–12. doi: 10.1053/plac.2000.0608. [DOI] [PubMed] [Google Scholar]
  • 12.Myatt L, Rosenfield RB, Eis AL, Brockman DE, Greer I, Lyall F. Nitrotyrosine residues in placenta. Evidence of peroxynitrite formation and action. Hypertension. 1996;28(3):488–93. doi: 10.1161/01.hyp.28.3.488. [DOI] [PubMed] [Google Scholar]
  • 13.Palm M, Axelsson O, Wernroth L, Basu S. F(2)-isoprostanes, tocopherols and normal pregnancy. Free Radic Res. 2009;43(6):546–52. doi: 10.1080/10715760902902737. [DOI] [PubMed] [Google Scholar]
  • 14.Morris JM, Gopaul NK, Endresen MJ, Knight M, Linton EA, Dhir S, Anggard EE, Redman CW. Circulating markers of oxidative stress are raised in normal pregnancy and pre-eclampsia. Br J Obstet Gynaecol. 1998;105(11):1195–9. doi: 10.1111/j.1471-0528.1998.tb09974.x. [DOI] [PubMed] [Google Scholar]
  • 15.Toescu V, Nuttall SL, Martin U, Kendall MJ, Dunne F. Oxidative stress and normal pregnancy. Clin Endocrinol (Oxf) 2002;57(5):609–13. doi: 10.1046/j.1365-2265.2002.01638.x. [DOI] [PubMed] [Google Scholar]
  • 16.Wisdom SJ, Wilson R, McKillop JH, Walker JJ. Antioxidant systems in normal pregnancy and in pregnancy-induced hypertension. Am J Obstet Gynecol. 1991;165(6 Pt 1):1701–4. doi: 10.1016/0002-9378(91)90018-m. [DOI] [PubMed] [Google Scholar]
  • 17.Zusterzeel PL, Rutten H, Roelofs HM, Peters WH, Steegers EA. Protein carbonyls in decidua and placenta of pre-eclamptic women as markers for oxidative stress. Placenta. 2001;22(2–3):213–9. doi: 10.1053/plac.2000.0606. [DOI] [PubMed] [Google Scholar]
  • 18.Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19(3):257–67. doi: 10.2337/diacare.19.3.257. [DOI] [PubMed] [Google Scholar]
  • 19.Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87(1):315–424. doi: 10.1152/physrev.00029.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lyall F, Gibson JL, Greer IA, Brockman DE, Eis AL, Myatt L. Increased nitrotyrosine in the diabetic placenta: evidence for oxidative stress. Diabetes Care. 1998;21(10):1753–8. doi: 10.2337/diacare.21.10.1753. [DOI] [PubMed] [Google Scholar]
  • 21.Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25(1):29–38. doi: 10.1161/01.ATV.0000150649.39934.13. [DOI] [PubMed] [Google Scholar]
  • 22.Many A, Westerhausen-Larson A, Kanbour-Shakir A, Roberts JM. Xanthine oxidase/dehydrogenase is present in human placenta. Placenta. 1996;17(5–6):361–5. doi: 10.1016/s0143-4004(96)90061-2. [DOI] [PubMed] [Google Scholar]
  • 23.Matsubara S, Sato I. Enzyme histochemically detectable NAD(P)H oxidase in human placental trophoblasts: normal, preeclamptic, and fetal growth restriction-complicated pregnancy. Histochem Cell Biol. 2001;116(1):1–7. doi: 10.1007/s004180100301. [DOI] [PubMed] [Google Scholar]
  • 24.Raijmakers MT, Peters WH, Steegers EA, Poston L. NAD(P)H oxidase associated superoxide production in human placenta from normotensive and pre-eclamptic women. Placenta. 2004;25 (Suppl A):S85–9. doi: 10.1016/j.placenta.2004.01.009. [DOI] [PubMed] [Google Scholar]
  • 25.Cheng G, Cao Z, Xu X, van Meir EG, Lambeth JD. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene. 2001;269(1–2):131–40. doi: 10.1016/s0378-1119(01)00449-8. [DOI] [PubMed] [Google Scholar]
  • 26.Griendling KK. Novel NAD(P)H oxidases in the cardiovascular system. Heart. 2004;90(5):491–3. doi: 10.1136/hrt.2003.029397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Cui XL, Brockman D, Campos B, Myatt L. Expression of NADPH oxidase isoform 1 (Nox1) in human placenta: involvement in preeclampsia. Placenta. 2006;27(4–5):422–31. doi: 10.1016/j.placenta.2005.04.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43(2):109–42. [PubMed] [Google Scholar]
  • 29.Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci U S A. 2004;101(12):4003–8. doi: 10.1073/pnas.0307446101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Beckmann JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler. 1994;375(2):81–8. doi: 10.1515/bchm3.1994.375.2.81. [DOI] [PubMed] [Google Scholar]
  • 31.Souza JM, Choi I, Chen Q, Weisse M, Daikhin E, Yudkoff M, Obin M, Ara J, Horwitz J, Ischiropoulos H. Proteolytic degradation of tyrosine nitrated proteins. Arch Biochem Biophys. 2000;380(2):360–6. doi: 10.1006/abbi.2000.1940. [DOI] [PubMed] [Google Scholar]
  • 32.MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry. 1998;37(6):1613–22. doi: 10.1021/bi971894b. [DOI] [PubMed] [Google Scholar]
  • 33.Zou MH, Leist M, Ullrich V. Selective nitration of prostacyclin synthase and defective vasorelaxation in atherosclerotic bovine coronary arteries. Am J Pathol. 1999;154(5):1359–65. doi: 10.1016/S0002-9440(10)65390-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Szabo C, Zingarelli B, O’Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A. 1996;93(5):1753–8. doi: 10.1073/pnas.93.5.1753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci U S A. 1996;93(26):15069–74. doi: 10.1073/pnas.93.26.15069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Aulak KS, Koeck T, Crabb JW, Stuehr DJ. Dynamics of protein nitration in cells and mitochondria. Am J Physiol Heart Circ Physiol. 2004;286(1):H30–8. doi: 10.1152/ajpheart.00743.2003. [DOI] [PubMed] [Google Scholar]
  • 37.Kuo WN, Kanadia RN, Shanbhag VP, Toro R. Denitration of peroxynitrite-treated proteins by ‘protein nitratases’ from rat brain and heart. Mol Cell Biochem. 1999;201(1–2):11–6. doi: 10.1023/a:1007024126947. [DOI] [PubMed] [Google Scholar]
  • 38.Low SY, Sabetkar M, Bruckdorfer KR, Naseem KM. The role of protein nitration in the inhibition of platelet activation by peroxynitrite. FEBS Lett. 2002;511(1–3):59–64. doi: 10.1016/s0014-5793(01)03279-3. [DOI] [PubMed] [Google Scholar]
  • 39.Koeck T, Fu X, Hazen SL, Crabb JW, Stuehr DJ, Aulak KS. Rapid and selective oxygen-regulated protein tyrosine denitration and nitration in mitochondria. J Biol Chem. 2004;279(26):27257–62. doi: 10.1074/jbc.M401586200. [DOI] [PubMed] [Google Scholar]
  • 40.Elfering SL, Haynes VL, Traaseth NJ, Ettl A, Giulivi C. Aspects, mechanism, and biological relevance of mitochondrial protein nitration sustained by mitochondrial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2004;286(1):H22–9. doi: 10.1152/ajpheart.00766.2003. [DOI] [PubMed] [Google Scholar]
  • 41.Souza JM, Daikhin E, Yudkoff M, Raman CS, Ischiropoulos H. Factors determining the selectivity of protein tyrosine nitration. Arch Biochem Biophys. 1999;371(2):169–78. doi: 10.1006/abbi.1999.1480. [DOI] [PubMed] [Google Scholar]
  • 42.Schopfer FJ, Baker PR, Freeman BA. NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? Trends Biochem Sci. 2003;28(12):646–54. doi: 10.1016/j.tibs.2003.10.006. [DOI] [PubMed] [Google Scholar]
  • 43.Kossenjans W, Eis A, Sahay R, Brockman D, Myatt L. Role of peroxynitrite in altered fetal-placental vascular reactivity in diabetes or preeclampsia. American Journal of Physiology Heart and Circulatory Physiology. 2000;278(4):H1311–H9. doi: 10.1152/ajpheart.2000.278.4.H1311. [DOI] [PubMed] [Google Scholar]
  • 44.Mudgett JS, Ding J, Guh-Siesel L, Chartrain NA, Yang L, Gopal S, Shen MM. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci U S A. 2000;97(19):10454–9. doi: 10.1073/pnas.180316397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Webster RP, Brockman D, Myatt L. Nitration of p38 MAPK in the placenta: association of nitration with reduced catalytic activity of p38 MAPK in pre-eclampsia. Mol Hum Reprod. 2006;12(11):677–85. doi: 10.1093/molehr/gal071. [DOI] [PubMed] [Google Scholar]
  • 46.Webster RP, Macha S, Brockman D, Myatt L. Peroxynitrite treatment in vitro disables catalytic activity of recombinant p38 MAPK. Proteomics. 2006;6(17):4838–44. doi: 10.1002/pmic.200600176. [DOI] [PubMed] [Google Scholar]
  • 47.Roberts VH, Webster RP, Brockman DE, Pitzer BA, Myatt L. Post-Translational Modifications of the P2X(4) purinergic receptor subtype in the human placenta are altered in preeclampsia. Placenta. 2007;28(4):270–7. doi: 10.1016/j.placenta.2006.04.008. [DOI] [PubMed] [Google Scholar]
  • 48.Baeten JM, Bukusi EA, Lambe M. Pregnancy complications and outcomes among overweight and obese nulliparous women. Am J Public Health. 2001;91(3):436–40. doi: 10.2105/ajph.91.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Rode L, Nilas L, Wojdemann K, Tabor A. Obesity-related complications in Danish single cephalic term pregnancies. Obstet Gynecol. 2005;105(3):537–42. doi: 10.1097/01.AOG.0000152304.39492.1c. [DOI] [PubMed] [Google Scholar]
  • 50.Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115(3):e290–6. doi: 10.1542/peds.2004-1808. [DOI] [PubMed] [Google Scholar]
  • 51.Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448–54. doi: 10.1161/01.CIR.0000158483.13093.9D. [DOI] [PubMed] [Google Scholar]
  • 52.Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006;83(2):461S–5S. doi: 10.1093/ajcn/83.2.461S. [DOI] [PubMed] [Google Scholar]
  • 53.Roberts VH, Smith J, McLea SA, Heizer AB, Richardson JL, Myatt L. Effect of increasing maternal body mass index on oxidative and nitrative stress in the human placenta. Placenta. 2009;30(2):169–75. doi: 10.1016/j.placenta.2008.11.019. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES